CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
A safety study of ANK-700 in patients with relapsing remitting multiple sclerosis. The study has two parts:Part A - first in human ...
Phase 1
Vienna, Virginia, United States and 14 other locations
Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis...
Phase 3
Washington, District of Columbia, United States and 73 other locations
will evaluate the pharmacokinetics, safety and tolerability, and immunogenicity of ocrelizumab administered subcutaneously to participants with multiple...
Phase 1
Washington, District of Columbia, United States and 20 other locations
Fatigue is a prevalent and disabling symptom in Multiple Sclerosis (MS), affecting up to 90% of patients. Current treatmen...
Phase 2
Baltimore, Maryland, United States
B-cells have an important role in the pathogenesis of multiple sclerosis (MS). Ocrelizumab, a medication that targets B-ce...
Phase 4
Baltimore, Maryland, United States
with fingolimod in children and adolescents with relapsing-remitting multiple sclerosis aged between 10 and \< 18 years over a dura...
Phase 3
Washington, District of Columbia, United States and 120 other locations
This study will evaluate if relapsing-remitting MS patients that have not had a relapse in the past year would benefit from a switch to ofat...
Phase 4
Lutherville, Maryland, United States and 33 other locations
Open-label study to evaluate the effectiveness of treatment with ofatumumab in subjects transitioning from any fumarate-based RMS approved therapy or...
Phase 3
Fairfax, Virginia, United States and 122 other locations
A single arm study evaluating the continued efficacy, safety and tolerability of ofatumumab in patients with relapsing multiple sclerosis...
Phase 3
Lutherville, Maryland, United States and 20 other locations
This study will evaluate the impact of ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) participants that are very early...
Phase 4
Washington, District of Columbia, United States and 35 other locations
Clinical trials
Research sites
Resources
Legal